13 completed, 2 recruiting, 1 terminated, 1 withdrawn. 17 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 13, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow Proteinuria: new trials by email Literature Review of Proteinuria trials Research Report on Proteinuria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria sparsentan, No sparsentan - Proteinuric Renal Disease, Proteinuric Kidney Disease | Phase 1 | Recruiting | Brigham and Women's Hospital | 20 | 2026-07-10 | 2026-07-30 |
| Mesenchymal Stem Cell Exosomes Alone or Combined With HUVEC Exosomes in Non-Dialysis Chronic Kidney Disease Human Wharton's jelly mesenchymal stem cell (HWJ-MSC) exosomes, Human umbilical vein endothelial cell (HUVEC) exosomes, Placebo (0.9% sodium chloride) - Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Phase 1 / Phase 2 | Completed | Nurhasan Agung Prabowo | 34 | 2026-07-01 | 2026-11-06 |
| Study of BHV-1400 in IgA Nephropathy BHV-1400 - IgA Nephropathy | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 20 | 2025-07-30 | 2026-06-23 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria ALXN1720 - Proteinuria | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2022-06-29 | 2023-06-29 |
| Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease | Phase 1 / Phase 2 | Completed | University of Aarhus | 57 | 2021-03-25 | 2025-04-11 |
| FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects GFB-887, Placebo - Healthy Volunteers | Phase 1 | Completed | Goldfinch Bio, Inc. | 70 | 2019-05-29 | 2020-06-02 |
| Pharmacokinetics of Apixaban in Nephrotic Syndrome apixaban - Nephrotic Syndrome, Proteinuria | Phase 1 | Completed | University of North Carolina, Chapel Hill | 21 | 2017-04-30 | 2019-07-24 |
| A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases N-acetyl D-mannosamine - Kidney Disease | Phase 1 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 10 | 2016-07-07 | 2023-02-24 |
| Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Apellis Pharmaceuticals, Inc. | 23 | 2015-12-01 | 2021-01-11 |
| The Role of Endothelin-1 in Sickle Cell Disease Ambrisentan, Placebo - Sickle Cell Anemia | Phase 1 | Completed | Augusta University | 26 | 2015-09-01 | 2020-04-02 |
| A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 | Completed | Apellis Pharmaceuticals, Inc. | 9 | 2015-02-23 | 2021-01-08 |
| A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine. ABT-614, Placebo Comparator - Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine | Phase 1 | Completed | Abbott | 16 | 2011-11-01 | 2012-08-22 |
| Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy OPL-CCL2-LPM - IGA Nephropathy, Proteinuria | Phase 1 | Terminated | Osprey Pharmaceuticals USA, Inc. | 30 | 2009-03-01 | 2010-06-02 |
| Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy FG-3019 - Diabetes Mellitus, Diabetic Nephropathy | Phase 1 | Completed | Kyntra Bio | 38 | 2008-03-01 | 2019-08-02 |
| Endothelin Receptor Antagonism in Proteinuric Nephropathy BQ-123 (selective endothelin A receptor antagonist), 0.9 % saline, Nifedipine - Chronic Kidney Disease, Proteinuria | Phase 1 | Completed | University of Edinburgh | 22 | 2006-05-01 | 2008-07-25 |
| Treatment Targets for Chronic Hypertension in Pregnancy methyldopa, labetalol, nifedipine - Pregnancy Toxemia, Hypertension | Phase 1 / Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2004-07-01 | 2017-01-30 | |
| Permeability Factor in Focal Segmental Glomerulosclerosis Plasma exchange, Cyclophosphamide - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 15 | 2000-12-01 | 2016-02-10 |
Renal Insufficiency, Chronic (5) · Kidney Diseases (4) · Nephrotic Syndrome (4) · Diabetic Nephropathies (3) · Glomerulonephritis (3) · Glomerulonephritis, IGA (3) · Glomerulosclerosis, Focal Segmental (3) · Anemia (2) · Diabetes Mellitus, Type 2 (2) · Hematologic Diseases (2) · Hemoglobinuria (2) · Hemoglobinuria, Paroxysmal (2) · Hemolysis (2) · Nephritis (2)
Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (17) · Urination Disorders (17) · Urogenital Diseases (17) · Urological Manifestations (17) · Urologic Diseases (15) · Kidney Diseases (8) · Pathologic Processes (7) · Chronic Disease (5) · Disease Attributes (5) · Renal Insufficiency (5) · Autoimmune Diseases (4)
Nifedipine (2) · Sodium Chloride (2) · apixaban (2) · pegcetacoplan (2) · Clonidine (1) · Cyclophosphamide (1) · Dalteparin (1) · Labetalol (1) · Methyldopa (1) · N-acetylmannosamine (1) · Plasma Exchange (1) · Plasmapheresis (1) · Saline Solution (1) · Sugars (1) · ambrisentan (1)
Apellis Pharmaceuticals, Inc. (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Abbott (1) · Alexion Pharmaceuticals, Inc. (1) · Augusta University (1) · Biohaven Therapeutics Ltd. (1) · Brigham and Women's Hospital (1) · Goldfinch Bio, Inc. (1) · Kyntra Bio (1) · Nurhasan Agung Prabowo (1) · Osprey Pharmaceuticals USA, Inc. (1) · University of Aarhus (1) · University of Edinburgh (1) · University of North Carolina, Chapel Hill (1) · Weill Medical College of Cornell University (1)
United States (11) · United Kingdom (2) · Canada (1) · Denmark (1) · Hong Kong (1) · Indonesia (1) · Malaysia (1) · New Zealand (1) · South Korea (1) · Thailand (1)
Federico Grossi, MD, PhD (2) · Jeffrey B Kopp, M.D. (2) · Abdullah Kutlar, MD (1) · Bryan Curtis, M.D. (1) · Daniel Crona, PharmD, PhD (1) · David J Webb, MD (1) · Dennis Andress, MD (1) · Jeanelle Kam, MD (1) · Michelle Hladunewich, M.D. (1) · Neeraj Dhaun, MBChB (1) · Phyllis August, MD MPH (1) · Sarah Kelddal, MD (1) · Tonang Dwi Ardyanto, dr., Sp.PK(K), Ph.D. (1) · Vimal Derebail, MD, MPH (1) · Vincent Pichette, M.D., Ph.D. (1)
PMID 35869170, PMID 37254256, PMID 39079163, PMID 40478760, PMID 41333097, PMID 41630898, PMID 41805697
U01HL117684 (1)